JPS6225125B2 - - Google Patents
Info
- Publication number
- JPS6225125B2 JPS6225125B2 JP53073367A JP7336778A JPS6225125B2 JP S6225125 B2 JPS6225125 B2 JP S6225125B2 JP 53073367 A JP53073367 A JP 53073367A JP 7336778 A JP7336778 A JP 7336778A JP S6225125 B2 JPS6225125 B2 JP S6225125B2
- Authority
- JP
- Japan
- Prior art keywords
- calcium
- vitamin
- serum
- diet
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000011575 calcium Substances 0.000 claims description 70
- 229910052791 calcium Inorganic materials 0.000 claims description 69
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 61
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 238000010304 firing Methods 0.000 claims description 9
- 241000237502 Ostreidae Species 0.000 claims description 8
- 235000020636 oyster Nutrition 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims 1
- 229960005069 calcium Drugs 0.000 description 68
- 235000005911 diet Nutrition 0.000 description 15
- 230000037213 diet Effects 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 13
- 229930003316 Vitamin D Natural products 0.000 description 10
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 235000019166 vitamin D Nutrition 0.000 description 10
- 239000011710 vitamin D Substances 0.000 description 10
- 150000003710 vitamin D derivatives Chemical class 0.000 description 10
- 229940046008 vitamin d Drugs 0.000 description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 6
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 6
- 239000001527 calcium lactate Substances 0.000 description 6
- 229960002401 calcium lactate Drugs 0.000 description 6
- 235000011086 calcium lactate Nutrition 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000002990 parathyroid gland Anatomy 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000548230 Crassostrea angulata Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OPSXJNAGCGVGOG-DKWTVANSSA-L Calcium L-aspartate Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CC([O-])=O OPSXJNAGCGVGOG-DKWTVANSSA-L 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 229910010413 TiO 2 Inorganic materials 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 229940034055 calcium aspartate Drugs 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- -1 silicate ion Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 229910001845 yogo sapphire Inorganic materials 0.000 description 1
Landscapes
- Meat, Egg Or Seafood Products (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7336778A JPS55332A (en) | 1978-06-17 | 1978-06-17 | Calcium agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7336778A JPS55332A (en) | 1978-06-17 | 1978-06-17 | Calcium agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS55332A JPS55332A (en) | 1980-01-05 |
JPS6225125B2 true JPS6225125B2 (da) | 1987-06-01 |
Family
ID=13516128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7336778A Granted JPS55332A (en) | 1978-06-17 | 1978-06-17 | Calcium agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS55332A (da) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01117833A (ja) * | 1987-10-29 | 1989-05-10 | Masatoshi Kato | 生物活性物質 |
JP2001240416A (ja) * | 2000-02-28 | 2001-09-04 | Shozo Hori | 多目的用途に適用するようにした貝殻粉とその製法 |
JP2001278793A (ja) * | 2000-03-29 | 2001-10-10 | Choya:Kk | 易吸収性カルシウム剤の製法 |
KR100380011B1 (ko) * | 2000-09-30 | 2003-04-11 | 허일엽 | 동·수산물 뼈·패류를 이용한 알칼리성 미네랄 음료의제조방법 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4885721A (da) * | 1972-02-16 | 1973-11-13 |
-
1978
- 1978-06-17 JP JP7336778A patent/JPS55332A/ja active Granted
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4885721A (da) * | 1972-02-16 | 1973-11-13 |
Also Published As
Publication number | Publication date |
---|---|
JPS55332A (en) | 1980-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU702073B2 (en) | Pharmaceutical composition containing selected lanthanum carbonate hydrates | |
Alfrey et al. | Bone magnesium pools in uremia | |
US5075499A (en) | Calcium supplementation by dicalcium citrate-lactate | |
JP4929426B2 (ja) | リン酸塩結合剤としての、混合または硫酸金属塩化合物 | |
RU2093160C1 (ru) | Фармацевтическая композиция и способ воздействия на ретикулоэндотелиальную систему, лечения муковисцидоза и хронических болевых синдромов, сопровождающих заболевания опорно-двигательного аппарата и онкологические заболевания | |
EP0159917B1 (en) | Pharmaceutical composition containing a hydroxypyrone-iron complex | |
Dock et al. | Cation exchangers: their use and hazards as aids in managing edema | |
US5006551A (en) | Composition for destroying malignant tumors | |
Fetner et al. | Effects of magnesium oxide on the crystallization of calcium salts in urine in patients with recurrent nephrolithiasis | |
US2958626A (en) | Basic aluminum magnesium carbonate | |
Morris et al. | The distribution of radioactivity following the feeding of carbon 14-labeled 2-acetylaminofluorene to rats | |
Van der Linden et al. | Pneumatosis cystoides coli associated with high H2 excretion: treatment with an elemental diet | |
JPS6225125B2 (da) | ||
US4968510A (en) | Method of treating arthritis | |
Meneely et al. | Intestinal maturation: in vivo magnesium transport | |
US6887897B2 (en) | Calcium glutarate supplement and phosphorus binder | |
US4098883A (en) | Aluminum compound and pharmaceutical compositions containing same | |
JPS5711919A (en) | Manufacture of antacid substance | |
US1526981A (en) | Effervescent alkali compound and process of manufacturing and preparing the same | |
Schaefer et al. | Calcium salts of ketoacids as a new treatment strategy for uremic hyperphosphatemia. | |
Mraz | Intestinal absorption of Ca-45 and Sr-85 as affected by the alkaline earths and pH. | |
US4840795A (en) | Preparation and method for effecting fat and lipid adsorption | |
Anelli et al. | Substitution of calcium carbonate for aluminum hydroxide in patients on hemodialysis: effects on acidosis, on parathyroid function, and on calcemia | |
JPS643848B2 (da) | ||
Kobayashi et al. | Role of prostaglandin E 2 on human gastric ulcers |